SANDOZ-DICLOFENAC SUPPOSITORY

국가: 캐나다

언어: 영어

출처: Health Canada

지금 구매하세요

Download 제품 특성 요약 (SPC)
06-01-2020

유효 성분:

DICLOFENAC SODIUM

제공처:

SANDOZ CANADA INCORPORATED

ATC 코드:

M01AB05

INN (국제 이름):

DICLOFENAC

복용량:

100MG

약제 형태:

SUPPOSITORY

구성:

DICLOFENAC SODIUM 100MG

관리 경로:

RECTAL

패키지 단위:

30

처방전 유형:

Prescription

치료 영역:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

제품 요약:

Active ingredient group (AIG) number: 0114417001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2021-01-25

제품 특성 요약

                                _Sandoz-Diclofenac and Sandoz-Diclofenac SR _
_ _
_Page 1 of 40 _
PRODUCT MONOGRAPH
PR
SANDOZ-DICLOFENAC
PR
SANDOZ-DICLOFENAC SR
(diclofenac sodium)
50 mg Enteric-Coated Tablets
75 and 100 mg Slow-Release Tablets
50 and 100 mg Suppositories
Acetic Acid Derivatives and Related Substances
Sandoz Canada Inc.
Date of revision:
110 Rue de Lauzon,
January 6, 2020
Boucherville, Quebec
J4B 1E6
Control no. 233855
_Sandoz-Diclofenac and Sandoz-Diclofenac SR _
_ _
_Page 2 of 40 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
15
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL INFORMATION
.................
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

제품 특성 요약 제품 특성 요약 프랑스어 06-01-2020

이 제품과 관련된 검색 알림